The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
D Jochmans, C Liu, K Donckers, A Stoycheva… - MBio, 2023 - Am Soc Microbiol
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle
and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors …
and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors …
Comparative evaluation of authorized drugs for treating Covid‐19 patients
Abstract Background and Aims Vaccines are the first line of defense against coronavirus
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
L Deng, C Li, Q Zeng, X Liu, X Li, H Zhang, Z Hong… - Journal of Infection, 2020 - Elsevier
Summary Background Corona Virus Disease 2019 (COVID-19) due to the 2019 novel
coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China …
coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China …
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - academic.oup.com
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19： a meta-analysis
W Wen, C Chen, J Tang, C Wang, M Zhou… - Annals of …, 2022 - Taylor & Francis
Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …
controlled. Although great achievements have been made in COVID-19 research and many …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
A multicenter phase 2 randomized controlled study on the efficacy and safety of reparixin in the treatment of hospitalized patients with COVID-19 pneumonia
Introduction Acute lung injury and acute respiratory distress syndrome are common
complications in patients with coronavirus disease 2019 (COVID-19). Poor outcomes in …
complications in patients with coronavirus disease 2019 (COVID-19). Poor outcomes in …
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients
A Jayk Bernal, MM Gomes da Silva… - … England Journal of …, 2022 - Mass Medical Soc
Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
[HTML][HTML] Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
JD Gunst, NB Staerke, MH Pahus, LH Kristensen… - …, 2021 - thelancet.com
Background The trans-membrane protease serine 2 (TMPRSS2) is essential for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy …